The Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) pathway is a conserved master regulator of immunity and myeloproliferation. Advanced understanding of this pathway has led to development of targeted inhibitors of Janus Kinases (Jakinibs). As a class, Jakinibs effectively treat a multitude of hematologic and inflammatory diseases. Given such success, use of Jakinibs for mitigation of atopic dermatitis is under active investigation. Herein, we review the evolving data on the safety and efficacy of Jakinibs in treatment of atopic dermatitis. While it is still early in the study of Jakinibs for atopic dermatitis, evidence identifies Jakinibs as effective alternatives to conventional therapies. Nonetheless, multiple large safety and efficacy trials are needed before widespread use of Jakinibs can be advocated for atopic dermatitis.

Janus激酶信号转导子和转录激活子（JAK-STAT）通路是免疫和骨髓增殖的保守主调节剂。对这种途径的深入了解导致了Janus Kinases（Jakinibs）靶向抑制剂的开发。作为一类，Jakinibs可有效治疗多种血液和炎症性疾病。有了这样的成功，正在积极研究使用Jakinibs缓解特应性皮炎。本文中，我们回顾了有关Jakinibs在治疗特应性皮炎中的安全性和有效性的不断发展的数据。尽管针对特应性皮炎的Jakinibs研究仍处于早期阶段，但有证据表明Jakinibs是传统疗法的有效替代品。尽管如此，